Vittorio Gebbia

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +12

Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial

C. Gridelli, Federica Perrone, Ciro Gallo et al. · JNCI Journal of the National Cancer Institute · 2003 · 795 citations · Full text

Medicine, Oncology, Pharmacology +12

Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell’Italia Meridionale

Giuseppe Colucci, Vittorio Gebbia, G Paoletti et al. · Journal of Clinical Oncology · 2005 · 781 citations

Medicine, Oncology, Pharmacotherapy +11

Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

Massimo Di Maïo, Ciro Gallo, Natasha B. Leighl et al. · Journal of Clinical Oncology · 2015 · 497 citations · Full text

Medicine, Oncology, Cancer Drug Toxicity Management +16

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.

Giuseppe Colucci, Francesco Giuliani, Vittorio Gebbia et al. · PubMed · 2002 · 385 citations

Medicine, Oncology, Pharmacology +16